As of 2026-04-04, the Intrinsic Value of Vaccibody AS (VACC.OL) is 3.92 NOK. This VACC.OL valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 45.80 NOK, the upside of Vaccibody AS is -91.40%.
The range of the Intrinsic Value is 2.68 - 9.96 NOK
Based on its market price of 45.80 NOK and our intrinsic valuation, Vaccibody AS (VACC.OL) is overvalued by 91.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 2.68 - 9.96 | 3.92 | -91.4% |
| DCF (Growth 10y) | 2.62 - 8.73 | 3.67 | -92.0% |
| DCF (EBITDA 5y) | 2.51 - 4.21 | 3.05 | -93.3% |
| DCF (EBITDA 10y) | 2.52 - 4.12 | 3.03 | -93.4% |
| Fair Value | 2.44 - 2.44 | 2.44 | -94.67% |
| P/E | 2.70 - 10.65 | 7.17 | -84.3% |
| EV/EBITDA | 3.04 - 11.93 | 5.81 | -87.3% |
| EPV | 3.60 - 4.76 | 4.18 | -90.9% |
| DDM - Stable | 6.26 - 39.38 | 22.82 | -50.2% |
| DDM - Multi | 1.61 - 7.86 | 2.67 | -94.2% |
| Market Cap (mil) | 13,145.15 |
| Beta | 1.08 |
| Outstanding shares (mil) | 287.01 |
| Enterprise Value (mil) | 12,972.57 |
| Market risk premium | 4.74% |
| Cost of Equity | 7.29% |
| Cost of Debt | 4.25% |
| WACC | 7.29% |